|A high-throughput colony formation assay for profiling novel compounds and RNAi reagents using the Acumen® eX3|
Andrew Goulter and Jason Mundin
Cell colony formation assays measure a cell's ability to grow unattached to a surface and have applications in a range of areas including hematopoietic stem cell research, cell transformation studies and the prediction of responses of tumors to chemotherapeutic agents. The results of this study demonstrated that Acumen eX3 can be used as a high-throughput platform for investigation of effects of test compounds and RNAi reagents on cell colony formation.
|Gene Expression Profiling of Archived FFPE Samples|
Silvia Rüberg, Sabine Classen, Jana Ciomperlik, Dirk Dietrich, Ines Dischinger, Alena Böttcher, Sabrina Schmitz and Bernhard Gerstmayer
According to the BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) about 8,000,000 formalin-fixed paraffin-embedded (FFPE) samples derived from a multitude of different diseases have been collected in medical centers and biobanks all over Europe during the last decades.
|New Culture Medium Creates Immune Tolerance Between Two Allogeneic Tissue Cells|
Victor Alexander, PhD.; Anthony Passerini, PhD; Emir Hodzic, PhD.
We discovered that in vitro high dose of Progesterone (P) together with FGFa, EGF, VEGF, LPS had dual effect on Liver tissue cells: increased multiplication of Hepatocytes and suppressed all non-parenchymal (NP) liver tissue cells and created immune tolerance between two allogeneic mice Liver tissue
|Role of PPARd in satellite cells and muscle differentiation|
Alison Angione and Shihuan Kuang
Investigating the result of PPARd mutation in the myogenic progenitor cells
|High content imaging based mapping of stem cell phenotypes|
Er Liu, Sebastian Vega, Anthony Kulesa, Jared Bushman, Hak-Joon Sung, Mattew Becker, Joachim Kohn, and Prabhas Moghe
Stem cells possess the ability of self-renewal and multi-lineage differentiation. However, conventional biological assays usually take weeks to months to identify the stem cell fates. Here we present a high content imaging based profiling platform that enables identifying stem cell phenotypes at much early time points. This platform could help monitor and even predict the long term fate of stem cells.
|Hepatitis B virus (HBV) and Human immunodeficiency virus (HIV) antibodies detected by peptide microarrays|
ahmed Abd El Wahed1, Ulrike Beutling2, Ronald Frank2, Gerhard Hunsmann1, and Hans-Joachim Fritz3
HBV and HIVenv chips with overlapping oligopeptides encompassing the full amino acid sequences of HBV and HIV polypeptides were produced. In addition, a chip displaying a library of random 4608 different 15-mers peptides (4608-RPL) was prepared. Both chips were used for analyzing monoclonal antibodies and sera from HIV- and HBV-infected individuals. 4608-RPL could be used for identifying target sequences of antibodies without prior knowledge of the corresponding immunizing antigen.
|SuperNatural: A Database of Available Natural Compounds|
Melanie Füllbeck, Mathias Dunkel and Robert Preissner
The majority of marketed drugs are natural compounds or derivatives thereof. The compounds availability is often unclear. Therefore we have compiled a database of ~50,000 natural compounds. Starting point for in silico screenings are about 2,500 well-known, classified natural compounds or imported molecules. Possible medical applications can be detected and about three million conformers computed to account for the flexibility during usage of the 3D-superposition algorithm.
|Nucleic Acid Reagents and Experimental Results in the NCBI Probe Database|
Svetlana Iazvovskaia, Ilene Karsch Mizrachi, Kirill Rotmistrovsky, and Savani Tatake
Five years ago, the NCBI Probe database (ProbeDB) was established to provide a centralized archive of molecular probes used in biomedical applications. Currently ProbeDB contains around 10 million probes of 65 types including gene silencing agents, in situ hybridization probes, and probes for variation analysis and genome mapping. Presently, ProbeDB is the largest and most extensive database of this type available in public domain.
|Regulatory requirements in the development of advanced therapy products (cell-, gene therapy, tissue engineering products)|
Regulatory authorities are active to ensure a good regulatory environment for somatic cell therapy-, gene therapy- and tissue engineering products (in the EU known as ‘Advanced Therapy Medicinal Products’). Both the EMEA and the FDA have, amongst others, issued guidelines to address the specific aspects of these products